Computed tomography perfusion imaging as a potential imaging biomarker of colorectal cancer

Table 1 Summary of previous reports on computed tomography perfusion and chemoradiation therapy in rectal cancer

Ref.	Year	Number of patients	Parameter changes	Response Prediction
Sahani et al[13]	2005	15	BF/decrease; MTT/increase	High baseline BF and low MTT associated with poor response
				(12 responders vs 3 non-responders)
Bellomi et al[25]	2007	20	BF, BV, PS/decrease	High baseline BF and BV associated with good response
				(17 responders vs 7 non-responders)
Curvo-Semedo et al[24]	2012	25	BF, BV, PS/decrease; MTT/increase	High baseline BF and low MTT associated with poor response
				(5 responders vs 15 non-responders)

BF: Blood flow; BV: Blood volume; MTT: Mean transit time; PS: Permeability surface area product.

Table 2 Summary of previous reports on computed tomography perfusion and antiangiogenic therapy in colorectal cancer

Ref.	Year	Number of patients	Time of CTP after the treatment	Parameter changes
Willet et al[18]	2004	6 (primary)	After 12 d of administration of bevacizumab	BF, BV/decrease
Willet et al[32]	2009	32 (primary)	After 12 d of administration of bevacizumab	BF, PS/decrease
Anzidei et al[33]	2011	18 (liver metastases)	After 181 d of the treatment (including bevacizumab)	BF, BV/slightly decrease (not significant)

CTP: Computed tomography perfusion; BF: Blood flow; BV: Blood volume; PS: Permeability surface area product.